Advanced Solid Malignancy
4 clinical trials · Condition
◉ Watch Advanced Solid Malignancy
| Record | Firm | Date |
|---|---|---|
| EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1) (NCT06923761) | Grey Wolf Therapeutics | 2023-05-21 |
| Comparison of Two Formulations of AZD5363 and the Effect of Food on Pharmacokinetic Exposure, Safety and Tolerability (NCT01895946) | AstraZeneca | 2013-12-01 |
| Open Label Phase 1 Study in Japan for Patient With Advanced Solid Malignancies (NCT01353781) | AstraZeneca | 2011-06-01 |
| Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules (NCT01226316) | AstraZeneca | 2010-12-01 |
Track Advanced Solid Malignancy automatically
Every clearance here is in the API, with alerts when new ones post.